BCTXW Overview

Funding Announcement: BRIACELL Therapeutics Corp has announced a funding initiative to provide up to $3 million for research and development (R&D) purposes.

Purpose of Funding: The funding is aimed at advancing the company's therapeutic programs and enhancing its research capabilities.

Royalty Agreement: BRIACELL THERAPEUTICS CORP has agreed to pay 2% royalties to TUMBC upon the commercialization of its products.

Commercialization Focus: The agreement emphasizes the importance of commercializing BRIACELL's therapeutic products in collaboration with TUMBC.

Agreement Overview: A new agreement has been reached for the purchase of exclusive soluble CD80 licenses.

Parties Involved: The agreement involves BRIACELL and a partner entity, indicating a strategic collaboration in the biotech sector.

Company Announcement: BRIACELL THERAPEUTICS has announced the closing of a public offering.

Financial Details: The offering raised a total of US$30 million.

BriaCell's Presentations at SABCS: BriaCell Therapeutics will present three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium, showcasing key biomarker data and survival results from their studies on Bria-IMT™ and other therapies for metastatic breast cancer.

Significant Data Sharing: The presentations include late-breaking clinical posters that aim to provide substantial data to leading breast cancer experts, with the goal of improving clinical outcomes for cancer patients.

Poster Presentation Details: Key presentations include topics on the impact of prior therapy and biomarkers in the Bria-ABC Phase 3 Trial, survival results from the Phase II Bria-IMT vaccine, and cytokine signatures as biomarkers of clinical benefit in breast cancer vaccination.

Company Overview: BriaCell is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance cancer care, with more information available on their website.

Bria-OTS+ Platform Overview: BriaCell Therapeutics has showcased its next-generation Bria-OTS+ platform, which demonstrates rapid and durable anti-cancer activity by engaging both innate and adaptive immune responses in preclinical models.

Preclinical Findings: The platform's lead candidates, Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer, have shown strong immune activation and sustained anti-cancer responses, indicating potential for prolonged clinical benefits.

Broad Applicability: The positive results from Bria-BRES+ and Bria-PROS+ suggest the Bria-OTS+ platform could be expanded to treat other solid tumors, highlighting its ability to generate potent immune responses across various cancer types.

Future Clinical Trials: BriaCell plans to confirm these preclinical findings in upcoming Phase 1/2a clinical studies, with Bria-PROS+ supported by a $2 million National Cancer Institute award.